CA3017778A1 - Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus - Google Patents

Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus Download PDF

Info

Publication number
CA3017778A1
CA3017778A1 CA3017778A CA3017778A CA3017778A1 CA 3017778 A1 CA3017778 A1 CA 3017778A1 CA 3017778 A CA3017778 A CA 3017778A CA 3017778 A CA3017778 A CA 3017778A CA 3017778 A1 CA3017778 A1 CA 3017778A1
Authority
CA
Canada
Prior art keywords
hbsag
antigen
hbcag
hepatitis
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3017778A
Other languages
English (en)
French (fr)
Inventor
Julio Cesar Aguilar Rubido
Yadira Lobaina Mato
Enrique Iglesias Perez
Eduardo Penton Arias
Gerardo Enrique Guillen Nieto
Jorge Agustin Aguiar Santiago
Sonia Gonzalez Blanco
Jorge VALDES HERNANDEZ
Mariela Vazquez Castillo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of CA3017778A1 publication Critical patent/CA3017778A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3017778A 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus Pending CA3017778A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2016-0038 2016-03-31
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
PCT/CU2017/050001 WO2017167317A1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Publications (1)

Publication Number Publication Date
CA3017778A1 true CA3017778A1 (en) 2017-10-05

Family

ID=58671308

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3017778A Pending CA3017778A1 (en) 2016-03-31 2017-03-14 Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus

Country Status (18)

Country Link
US (2) US11491218B2 (enExample)
EP (1) EP3437654B1 (enExample)
JP (1) JP6981992B2 (enExample)
KR (1) KR20180125985A (enExample)
CN (1) CN109219449B (enExample)
AR (1) AR108009A1 (enExample)
AU (1) AU2017243136B2 (enExample)
BR (1) BR112018069738A2 (enExample)
CA (1) CA3017778A1 (enExample)
CU (1) CU24454B1 (enExample)
EA (1) EA201892212A1 (enExample)
ES (1) ES2965709T3 (enExample)
MX (1) MX2018011793A (enExample)
MY (1) MY202118A (enExample)
TW (1) TWI755383B (enExample)
UA (1) UA128952C2 (enExample)
WO (1) WO2017167317A1 (enExample)
ZA (1) ZA201806325B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020355020A1 (en) * 2019-09-23 2022-04-28 Ascendo Biotechnology, Inc. Biodegradable nanocomplex vaccines, methods for suppression of hepapitis B virus replication and hepapitis B virus surface antigen secretion
CU20200028A7 (es) 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
CN116218881B (zh) * 2022-10-21 2024-08-13 山东大学 一种治疗或者预防乙肝病毒的疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CN1164331C (zh) * 2001-05-23 2004-09-01 中国人民解放军第二军医大学 一种人乙型肝炎核酸疫苗
CU23740A1 (es) 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN110859961A (zh) * 2013-07-26 2020-03-06 复旦大学 病毒免疫治疗药物复合物在制备治疗hbv感染药物中的应用

Also Published As

Publication number Publication date
EP3437654B1 (en) 2023-09-20
ZA201806325B (en) 2020-08-26
EA201892212A1 (ru) 2019-03-29
HK1259329A1 (zh) 2019-11-29
MY202118A (en) 2024-04-04
CU20160038A7 (es) 2017-11-07
JP2019510064A (ja) 2019-04-11
ES2965709T3 (es) 2024-04-16
CN109219449B (zh) 2022-08-30
AR108009A1 (es) 2018-07-04
AU2017243136B2 (en) 2022-02-17
CU24454B1 (es) 2019-11-04
UA128952C2 (uk) 2024-12-11
WO2017167317A1 (es) 2017-10-05
US20220193228A1 (en) 2022-06-23
EP3437654A1 (en) 2019-02-06
US20200297840A1 (en) 2020-09-24
TWI755383B (zh) 2022-02-21
US11491218B2 (en) 2022-11-08
CN109219449A (zh) 2019-01-15
KR20180125985A (ko) 2018-11-26
US11759517B2 (en) 2023-09-19
JP6981992B2 (ja) 2021-12-17
AU2017243136A1 (en) 2018-10-11
TW201735945A (zh) 2017-10-16
MX2018011793A (es) 2018-12-17
BR112018069738A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
US11759517B2 (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus
Michel et al. Hepatitis B vaccines: protective efficacy and therapeutic potential
TWI504608B (zh) 治療或預防ｂ型肝炎病毒感染之組合物及方法
JP2021506767A (ja) Ｂ型肝炎免疫化レジメン及び組成物
US20180028635A1 (en) Composition and uses thereof
San Zhao et al. DNA-based vaccination induces humoral and cellular immune responses against hepatitis B virus surface antigen in mice without activation of C-myc
JP2021506771A (ja) Ｂ型肝炎免疫化レジメン及び組成物
JP2013505971A (ja) 治療上の免疫化後の細胞性刺激のためのｂ型肝炎ウイルス抗原製剤
CN101309931B (zh) 包含截短的hbc核心蛋白和基于皂苷的佐剂的疫苗
HK1259329B (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
CN103566369B (zh) 一种在慢性乙肝病毒感染状态下诱导机体产生特异性免疫的乙肝疫苗
EA040981B1 (ru) Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b
RU2362586C2 (ru) Фармацевтические композиции для терапевтического применения
US20220288187A1 (en) Biodegradable nanocomplex vaccines, methods for suppression of hepapitis b virus replication and hepapitis b virus surface antigen secretion

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220218

EEER Examination request

Effective date: 20220218

EEER Examination request

Effective date: 20220218

EEER Examination request

Effective date: 20220218

EEER Examination request

Effective date: 20220218

EEER Examination request

Effective date: 20220218